Back to Search
Start Over
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma.
- Source :
-
Haematologica [Haematologica] 2024 Jul 01; Vol. 109 (7), pp. 2337-2340. Date of Electronic Publication: 2024 Jul 01. - Publication Year :
- 2024
- Subjects :
- Humans
Antibodies, Monoclonal, Humanized therapeutic use
Drug Resistance, Neoplasm drug effects
Treatment Outcome
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Antineoplastic Combined Chemotherapy Protocols adverse effects
Recurrence
Male
Antineoplastic Agents therapeutic use
Female
Multiple Myeloma drug therapy
Multiple Myeloma pathology
Subjects
Details
- Language :
- English
- ISSN :
- 1592-8721
- Volume :
- 109
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Haematologica
- Publication Type :
- Editorial & Opinion
- Accession number :
- 38385280
- Full Text :
- https://doi.org/10.3324/haematol.2023.284694